Skip to main content

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Publication ,  Journal Article
Xu-Monette, ZY; Tu, M; Jabbar, KJ; Cao, X; Tzankov, A; Visco, C; Nagarajan, L; Cai, Q; Montes-Moreno, S; An, Y; Dybkaer, K; Chiu, A; Orazi, A ...
Published in: Oncotarget
March 2015

CD5 is a pan-T-cell surface marker and is rarely expressed in diffuse large B-cell lymphoma (DLBCL). Large-scale studies of de novo CD5+ DLBCL are lacking in Western countries. In this study by the DLBCL Rituximab-CHOP Consortium, CD5 was expressed in 5.5% of 879 DLBCL patients from Western countries. CD5+ DLBCL was associated with higher frequencies of >1 ECOG performance status, bone marrow involvement, central nervous system relapse, activated B-cell-like subtype, Bcl-2 overexpression, and STAT3 and NF-κB activation, whereas rarely expressed single-stranded DNA-binding protein 2 (SSBP2), CD30 or had MYC mutations. With standard R-CHOP chemotherapy, CD5+ DLBCL patients had significantly worse overall survival (median, 25.3 months vs. not reached, P< .0001) and progression-free survival (median, 21.3 vs. 85.8 months, P< .0001) than CD5- DLBCL patients, which was independent of Bcl-2, STAT3, NF-κB and the International Prognostic Index. Interestingly, SSBP2 expression abolished the prognostic significance of CD5 expression, suggesting a tumor-suppressor role of SSBP2 for CD5 signaling. Gene-expression profiling demonstrated that B-cell receptor signaling dysfunction and microenvironment alterations are the important mechanisms underlying the clinical impact of CD5 expression. This study shows the distinctive clinical and biological features of CD5+ DLBCL patients in Western countries and underscores important pathways with therapeutic implications.

Duke Scholars

Published In

Oncotarget

DOI

EISSN

1949-2553

ISSN

1949-2553

Publication Date

March 2015

Volume

6

Issue

8

Start / End Page

5615 / 5633

Related Subject Headings

  • Treatment Outcome
  • Tissue Array Analysis
  • Prognosis
  • Middle Aged
  • Male
  • Lymphoma, Large B-Cell, Diffuse
  • Immunohistochemistry
  • Humans
  • Gene Expression Profiling
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xu-Monette, Z. Y., Tu, M., Jabbar, K. J., Cao, X., Tzankov, A., Visco, C., … Young, K. H. (2015). Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 6(8), 5615–5633. https://doi.org/10.18632/oncotarget.3479
Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carol Visco, Lalitha Nagarajan, et al. “Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Oncotarget 6, no. 8 (March 2015): 5615–33. https://doi.org/10.18632/oncotarget.3479.
Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar;6(8):5615–33.
Xu-Monette, Zijun Y., et al. “Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Oncotarget, vol. 6, no. 8, Mar. 2015, pp. 5615–33. Epmc, doi:10.18632/oncotarget.3479.
Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar;6(8):5615–5633.

Published In

Oncotarget

DOI

EISSN

1949-2553

ISSN

1949-2553

Publication Date

March 2015

Volume

6

Issue

8

Start / End Page

5615 / 5633

Related Subject Headings

  • Treatment Outcome
  • Tissue Array Analysis
  • Prognosis
  • Middle Aged
  • Male
  • Lymphoma, Large B-Cell, Diffuse
  • Immunohistochemistry
  • Humans
  • Gene Expression Profiling
  • Female